Study finds that subretinal AAV8 injections provoke immune response in retinal diseases treatment.
- Study shows AAV8 injections in rd10 mice lead to a proinflammatory T-cell immune response against the transgene product.
- Co-injection of immunodominant peptides with AAV8 can modulate the immune response at various doses.
- Results suggest AAV8 injections induce peripheral T-cell responses that can be controlled by subretinal associated immune inhibition (SRAII) mechanism.
- Long-term follow-up of AAV-based therapy for retinal diseases has revealed inflammatory events and visual field reduction in some patients.
- Research provides insights into antigen-specific immune modulatory effects for AAV gene therapy trials in retinal diseases.
Source link
Infectious Diseases,HIV/AIDS,Rheumatology